Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

FDA Drug Safety Newsletter - Volume 1, Number 3, Spring 2008

This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting. For more information, visit the FDA Drug Safety Newsletter Fact Sheet.
    

In This Issue
 

Editor's Note

Postmarketing Reviews

Reports of radiation recall associated with pemetrexed (marketed as ALIMTA)

Reports of serious liver injury associated with natalizumab (marketed as TYSABRI)

Reports of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with carbamazepine (marketed as CARBATROL, EQUETRO, TEGRETOL and other associated generics) in Asians positive for the HLA-B*1502 allele

Drug Safety Communications

 physician, patient in bed, pills

U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
5600 Fishers Lane, Rockville MD 20857-0001
Phone: 1-888-INFO-FDA (1-888-463-6332)

Renan A. Bonnel, PharmD, MPH
Senior Scientific Editor

Gregory D. Busse, PhD
Editor

Contributing Authors:
Charlene Flowers, RPh, Mark Avigan, MD, CM (natalizumab)
Ron Farkas, MD, PhD (carbamazepine)

Art Direction and Design: Michael Ermarth

Acknowledgments:
Office of Surveillance and Epidemiology and Office of New Drugs

We value your comments. Please let us know by reaching us at Comments. All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

 

Page created: June 12, 2008
-
-